Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

Next Previous
Search
Trial Profile

A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Zanubrutinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 15 Jun 2023 Results of pooled analysis from (BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002,BGB-3111-GA-101) assessing comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies presented at the 28th Congress of the European Haematology Association
    • 05 Oct 2021 The primary end-point "Number of participants with adverse events" has been replaced by 5 new primary end-points 4 of which focus on AR while Partial response focuses on TU.
    • 29 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top